- Home
- SCNX vs AADI Comparison
SCNX vs AADI Comparison
Compare SCNX & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- AADI
- Stock Information
- Founded
- SCNX 2010
- AADI 2011
- Country
- SCNX United States
- AADI United States
- Employees
- SCNX N/A
- AADI N/A
- Industry
- SCNX Other Pharmaceuticals
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- AADI Health Care
- Exchange
- SCNX Nasdaq
- AADI Nasdaq
- Market Cap
- SCNX 59.2M
- AADI 59.4M
- IPO Year
- SCNX 2020
- AADI N/A
- Fundamental
- Price
- SCNX $7.92
- AADI $2.96
- Analyst Decision
- SCNX
- AADI Hold
- Analyst Count
- SCNX 0
- AADI 3
- Target Price
- SCNX N/A
- AADI $1.75
- AVG Volume (30 Days)
- SCNX 13.8K
- AADI 615.0K
- Earning Date
- SCNX 02-10-2025
- AADI 11-06-2024
- Dividend Yield
- SCNX N/A
- AADI N/A
- EPS Growth
- SCNX N/A
- AADI N/A
- EPS
- SCNX 3.55
- AADI N/A
- Revenue
- SCNX N/A
- AADI $25,070,000.00
- Revenue This Year
- SCNX $1,085.75
- AADI $10.15
- Revenue Next Year
- SCNX N/A
- AADI $5.32
- P/E Ratio
- SCNX $3.23
- AADI N/A
- Revenue Growth
- SCNX 166.67
- AADI 7.80
- 52 Week Low
- SCNX $3.69
- AADI $1.21
- 52 Week High
- SCNX $44.56
- AADI $3.60
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- AADI 74.24
- Support Level
- SCNX N/A
- AADI $2.07
- Resistance Level
- SCNX N/A
- AADI $3.60
- Average True Range (ATR)
- SCNX 0.00
- AADI 0.22
- MACD
- SCNX 0.00
- AADI 0.07
- Stochastic Oscillator
- SCNX 0.00
- AADI 74.51
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.